Squalamine Lactate Ophthalmic Solution, 0.2%

DRUG3 trials

Sponsors

Ohr Pharmaceutical Inc.

Conditions

Age-Related Macular DegenerationAge-related Macular DegenerationMacular EdemaRetinal Vein Occlusion

Phase 1

Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion

CompletedNCT02614937

Ohr Pharmaceutical Inc.Macular Edema, Retinal Vein Occlusion

Start: 2013-04-30End: 2014-12-31Updated: 2015-11-25

Phase 2

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

WithdrawnNCT02511613

Ohr Pharmaceutical Inc.Age-Related Macular Degeneration

Start: 2015-07-31End: 2016-04-30Updated: 2017-04-27

Phase 3

Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

Ohr Pharmaceutical Inc.Age-related Macular Degeneration

Start: 2016-04-12End: 2017-12-31Updated: 2017-04-27

Related Papers

Biologically-active sulfated steroids: synthesis and state-of-art

2018-10-31